Skip to main content
Log in

New Insights into the Second Generation Antihistamines

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Second generation antihistamines are recognised as being highly effective treatments for allergy-based disease and are among the most frequently prescribed and safest drugs in the world. However, consideration of the therapeutic index or the benefit/risk ratio of the H1 receptor antagonists is of paramount importance when prescribing this class of compounds as they are used to treat non-life threatening conditions. There are many second generation antihistamines available and at first examination these appear to be comparable in terms of safety and efficacy. However, the newer antihistamines in fact represent ahererogeneous group of compounds, having markedly differing chemical structures, adverse effects, half-life, tissue distribution and metabolism, spectrum of antihistaminic properties, and varying degrees of anti-inflammatory effects. With regard to the latter, there is growing awareness that some of these compounds might represent useful adjunct medications in asthma therapy. In terms of safety issues, the current second generation grouping includes compounds with proven cardiotoxic effects and others with the potential for adverse drug interactions. Moreover, some of the second generation H1 antagonists have given cause for concern regarding their potential to cause a degree of somnolence in some individuals. It can be argued, therefore, that the present second generation grouping is too large and indistinct since this was based primarily on the concept of separating the first generation sedating compounds from nonsedating H1 antagonists. Although it is too early to talk about a third generation grouping of antihistamines, future membership of such a classification could be based on a low volume of distribution coupled with a lack of sedating effects, drug interactions and cardiotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Table III
Table IV
Fig. 3
Fig. 4
Table V
Table VI

Similar content being viewed by others

References

  1. Beasley R, Keil U, von Mutius E, et al., on behalf of the International Study of Asthma and Allergies in Children (ISSAC). Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, atopic eczema: ISSAC. Lancet 1998; 351: 1225–32

    Article  Google Scholar 

  2. Nicholson AN, Pascoe PA, Stone BM. Histaminergic systems and sleep-studies in man with H1 and H2 antagonists. Neuropharmacology 1985; 24: 245–50

    Article  PubMed  CAS  Google Scholar 

  3. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991; 67: 625–33

    PubMed  CAS  Google Scholar 

  4. Simons FER. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994; 10: 350–80

    Article  PubMed  CAS  Google Scholar 

  5. Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists: an EAACI position paper. Allergy 1996; 51: 666–75

    PubMed  CAS  Google Scholar 

  6. Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacotherapy 1995; 66: 413–63

    CAS  Google Scholar 

  7. Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease. New York (NY): Marcel Dekker Inc, 1996: 383–412

    Google Scholar 

  8. Lown KS, Lolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by erythromycin breath test. Drug Metab Disp 1994; 22: 947–55

    CAS  Google Scholar 

  9. Delauche-Cavallier MC, Chaufour S, Guerault E, et al. QT interval monitoring during clinical studies with mizolastine, a new antistamine. Clin Exp Allergy 1999; 29 Suppl. 3: 206–11

    Article  PubMed  CAS  Google Scholar 

  10. Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987; 5: 931–4

    Google Scholar 

  11. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46: 1055–80

    Article  PubMed  CAS  Google Scholar 

  12. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55: 269–74

    Article  PubMed  CAS  Google Scholar 

  13. Parkinson A, Clement RP, Casciano CN, et al. Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rat and mice. Biochem Pharmacol 1992; 43: 2169–80

    Article  PubMed  CAS  Google Scholar 

  14. Nakamura K, Yokoi T, Kodama T, et al. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 1998; 284: 437–42

    PubMed  CAS  Google Scholar 

  15. Hu YP, Robert J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 1995; 50: 169–75

    Article  PubMed  CAS  Google Scholar 

  16. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992; 30: 165–73

    Article  PubMed  CAS  Google Scholar 

  17. Hait WN, Gesmonde JF, Murren JR, et al. Terfenadine (seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993; 45: 401–6

    Article  PubMed  CAS  Google Scholar 

  18. Fisher GA, Lum BL, Hausdorff J, et al. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32: 1082–6

    Article  Google Scholar 

  19. Desager J-P, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1 antihistamines. Clin Pharmacokinet 1995; 28: 419–32

    Article  PubMed  CAS  Google Scholar 

  20. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269(12): 1513–8

    Article  PubMed  CAS  Google Scholar 

  21. Honig P, Wortham DC, Zamani K, et al. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7: 148–56

    Article  CAS  Google Scholar 

  22. Wilson J. An open-label interaction study between a single dose of ebastine and multiple doses of erythromycin on the cardiac function and pharmacokinetic profile in healthy adult male volunteers. Report no. EBA 130. Collegeville: Rhône-Poulenc Rorer, 1994. (Data on file)

  23. Wilson J. An open-label interaction study between a single dose of ebastine and multiple doses of ketoconazole on the cardiac function and pharmacokinetic profile in healthy adult male volunteers Report No. EBA 127. Collegeville: Rhône-Poulenc Rorer, 1994. (Data on file)

  24. Schering Corporation. Clarityn® [package insert]. Kenilworth: Schering Corporation, 2000

  25. Van Peer A, Crabbé R, Woestenborghs R, et al. Ketoconazole inhibits loratadine metabolism in man [abstract no. 1234]. Allergy 1993; 48 Suppl.: 34

    Google Scholar 

  26. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999; 29 Suppl. 3: 116–24

    Article  PubMed  CAS  Google Scholar 

  27. Harris SI. A multiple dose study to determine the interaction of cetirizine with ketoconazole in young healthy males [external report]. Pfizer, Study 93CK16-0604 (UCB code: RRCE93K 1202; 8500)

  28. Sale ME, Woosley RL, Thakker K, et al. Effects of cetirizine and erythromycin, alone and in combination, on QT interval and pharmacokinetics in healthy subjects [abstract no 15]. Ann Allergy Asthma Immunol 1996; 76: 93

    Google Scholar 

  29. Sale ME, Woosley R, Thakker K, et al. Arandomized, placebo-controlled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine [abstract no 14]. Ann Allergy Asthma Immunol 1996; 76: 93

    Google Scholar 

  30. van Peer A, Crabbe R, Woestenborghs R, et al. Ketoconazole inhibits loratadine metabolism in man. Allergy 1993; 48 Suppl. 16: 34

    Google Scholar 

  31. Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia [abstract]. Am J Cardiol 1994; 74: 207

    Article  PubMed  CAS  Google Scholar 

  32. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58: 269–78

    Article  PubMed  CAS  Google Scholar 

  33. McQuade RD, Richlan K, Duffy RA, et al. In vivo binding properties of non-sedating antihistamines to CNS histamine receptors. Drug Dev Res 1990; 20: 301–6

    Article  CAS  Google Scholar 

  34. Chesne C, Dehouck MP, Jolliet-Riant P, et al. Drug transfer across the blood-brain barrier: comparison of in vitro and in vivo models. Adv Exp Med Biol 1993; 331: 113–5

    Article  PubMed  CAS  Google Scholar 

  35. Haaksma EEJ, Leurs R, Timmerman H. Histamine receptors: subclasses and specific ligands. Pharmacotherapy 1990; 47: 73–104

    CAS  Google Scholar 

  36. Quach TT, Duchemin AM, Rose C, et al. In vivo occupation of cerebral histamine H1 receptors evaluated with [3H] mepyramine may predict sedative properties of psychotropic drugs. Eur J Pharmacol 1979; 60: 391–6

    Article  PubMed  CAS  Google Scholar 

  37. Nicholson AN, Pascoe PA, Turner C, et al. Sedation and histamine H1 receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270–6

    Article  PubMed  CAS  Google Scholar 

  38. Uzan A, LeFur G, Malgouris C. Are antihistamines sedative via a blockade of brain H1 receptors? J Pharm Pharmacol 1979; 31: 701–2

    Article  PubMed  CAS  Google Scholar 

  39. Ahn HS, Barnett A. Selective displacement of [3H] mepyramine from peripheral versus central nervous system receptors by loratadine, a non-selective antihistamine. Eur J Pharmacol 1986; 127: 153–5

    Article  PubMed  CAS  Google Scholar 

  40. Ter Laak AM, Donne-Op den Kelder GM, Bast A, et al. Is there a difference in the affinity of histamine H1 receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993; 232: 199–5

    Article  PubMed  Google Scholar 

  41. Yamashita M, Fukui H, Sugama K, et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci U S A 1991; 88: 11515–9

    Article  PubMed  CAS  Google Scholar 

  42. Reed DJ. Drug transport into the central nervous system. In: Glaser GH, Pentry JK, Woodburn DM, et al., editors. Antiepilectic drugs: mechanisms of action. New York (NY): Raven Press, 1980: 199–205

    Google Scholar 

  43. Hansch C, Bjorkroth JP, Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 1987; 76: 663–87

    Article  PubMed  CAS  Google Scholar 

  44. Ter Laak AM, Tsai RS, Donne-Op den Kelder GM, et al. Lipophilicity and hydrogen bond capacity of H1-antihistaminic agents in relation to their central sedative effects. Eur J Pharm Sci 1994; 2: 373–84

    Article  Google Scholar 

  45. Young RC, Mitchell RC, Brown TH, et al. Development of a new physiological model for brain penetration and its application to the design of centrally acting H2-receptor histamine antagonists. J Med Chem 1998; 31: 656–71

    Article  Google Scholar 

  46. Tillement J-P, Albengres E. Can the distribution of a drug in the body be directed towards its site-specific targets? The example of antihistamines (histamine H1-receptor antagonists) and cetirizine. Eur Ann Allergy Clin Immunol 1996; 28: 1–4

    Google Scholar 

  47. Tillement JP, Houin G, Zini R, et al. The binding of drugs to blood plasma macromolecules: recent advances and therapeutic significance. Adv Drug Res 1984; 13: 60–94

    Google Scholar 

  48. Simons FER, Simons KJ, Menger C, et al. The comparative pharmacokinetics of H1-receptor antagonists. Ann Allergy 1987; 59: 20–4

    PubMed  CAS  Google Scholar 

  49. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990; 20: 3–17

    Article  PubMed  Google Scholar 

  50. Pagliara A, Testa B, Carrupt PA, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem 1998; 41: 853–63

    Article  PubMed  CAS  Google Scholar 

  51. Volkerts ER, Vanwilligenburg APP, Vanlaar MW, et al. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharm 1992; 7: 227–38

    Article  CAS  Google Scholar 

  52. Walsh JK, Muehlbach MJ, Humm T, et al. Sleepiness and performance during three days’ use of cetirizine or diphenhydranie [abstract]. J Allergy Clin Immunol 1994; 93: 235

    Google Scholar 

  53. Nicholson AN, Stone BM. Antihistamines: impaired performance and the tendency to sleep. Eur J Clin Pharmacol 1986; 30: 27–32

    Article  PubMed  CAS  Google Scholar 

  54. Nicholson AN, Pascoe PA, Turner C, et al. Alertness and performance in man with enantiomers of chlophemiramine and dimethidine. Br J Clin Pharmacol 1989; 23: 734–5

    Google Scholar 

  55. Kay GG, Harris AG. Loratadine, a non-sedating antihistamine. Clin Exp Allergy 1999; 29 Suppl. 3: 147–50

    Article  PubMed  CAS  Google Scholar 

  56. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200–6

    Article  PubMed  CAS  Google Scholar 

  57. Nicholson AN, Stone BM, Turner C, et al. Antihistamines and aircrew: usefulness of fexofenadine. Aviat Space Environ Med 2000; 71: 2–6

    PubMed  CAS  Google Scholar 

  58. Marshall PS, Colon EA. Effects of the allergy season on mood and cognitive function. Ann Allergy 1993; 71: 251–8

    PubMed  CAS  Google Scholar 

  59. Spaeth J, Klimek L, Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996; 51: 893–906

    PubMed  CAS  Google Scholar 

  60. Vurman EFPM, Vanveggel LMA, Uiterwijk MMC, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6

    Google Scholar 

  61. Meltzer EIO, Welch MJ. Adverse effects of H1 -receptor antagonists in the central nervous system. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease: clinical allergy Immunology series. New York (NY): Marcel Dekker Inc, 1996: 357–81

    Google Scholar 

  62. DuBuske L. Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis. Ann Allergy 1995; 74: 345–54

    CAS  Google Scholar 

  63. Hindmarch I, Bhatti JZ. The effects of terfenadine with or without alcohol on an aspect of driving performance. Clin Exp Allergy 1989; 19: 609–11

    Article  PubMed  Google Scholar 

  64. Roth T, Roehrs T, Koshorek G, et al. Sedative effects of antihistamines. J Allergy Clin Immunol 1987; 80: 94–8

    Article  PubMed  CAS  Google Scholar 

  65. Falliers CJ, Brandon ML, Buchman E, et al. Double blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991; 66: 257–62

    PubMed  CAS  Google Scholar 

  66. Hindmarch I, Shamsi Z. Models to assess sedative properties of antihistamines. Clin Exp Allergy 1999; 29 Suppl. 3: 133–42

    Article  PubMed  CAS  Google Scholar 

  67. Mattila MJ, Paakkari I. Variations among the non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999; 55: 85–93

    Article  PubMed  CAS  Google Scholar 

  68. Simons FER. H1 receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83: 481–8

    Article  PubMed  CAS  Google Scholar 

  69. Horak F, Stubner UP. Comparative tolerability of second generation antihistamines. Drug Saf 1999; 20: 385–401

    Article  PubMed  CAS  Google Scholar 

  70. O’Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94. Allergy 1995; 50: 234–42

    Article  PubMed  Google Scholar 

  71. Canonica GW, Holgate ST, Karlsson G, et al. The impact of allergic rhinitis on quality of life and other airway diseases. Allergy 1998; 53 Suppl. 1–31

    Google Scholar 

  72. Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs 1999; 57: 31–47

    Article  PubMed  CAS  Google Scholar 

  73. Lockey RF, Widiltz MD, Mitchell DQ, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 76: 448–1

    Article  PubMed  CAS  Google Scholar 

  74. Harvey RP, Comer C, Sanders S, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 1233–41

    Article  PubMed  CAS  Google Scholar 

  75. Mansmann HC, Altaian LA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992; 68: 348–53

    PubMed  Google Scholar 

  76. Berkowitz RB, Dockhorn R, Lockey R, et al. Comparison of efficacy, safety and skin test inhibition of cetirizine and astemizole. Ann Allergy Asthma Immunol 1996; 76: 363–8

    Article  PubMed  CAS  Google Scholar 

  77. Chaweewan B, Jareonchai P, Dhorranintra B. A clinical comparison of cetirizine versus astemizole in perennial allergic rhinitis. Drug Invest 1993; 5: 222–8

    Article  Google Scholar 

  78. Broide DH, Love S, Altaian R, et al. Evaluation of cetirizine in the treatment of patients with seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1988; 81: 176

    Article  Google Scholar 

  79. Panayotopoulos SM, Panayotopoulos ES. Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Ann Allergy 1990; 65: 146–8

    PubMed  CAS  Google Scholar 

  80. Renton R, Fidler C, Rosenberg R. Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetirizine, 10 mg, in perennial allergic rhinitis. Ann Allergy 1991; 67: 416–20

    PubMed  CAS  Google Scholar 

  81. Kaiser HB. H1-receptor antagonist treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990; 86: 1000–3

    Article  PubMed  CAS  Google Scholar 

  82. Berman BA. Perennial allergic rhinitis: clinical efficacy of a new antihistamine. J Allergy Clin Immunol 1990; 86: 1004–8

    Article  PubMed  CAS  Google Scholar 

  83. Braunstein G, Malaquin F, Fajac I, et al. Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. Br J Clin Pharmacol 1992; 33: 445–8

    Article  PubMed  CAS  Google Scholar 

  84. Davies BH. Prophylactic treatment of seasonal allergic rhinitis. Clin Ther 1991; 13: 87–91

    PubMed  CAS  Google Scholar 

  85. Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990; 86: 1014–8

    Article  PubMed  CAS  Google Scholar 

  86. Kint A, Constandt L, Arendt C, et al. Comparative efficacy of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Acta Ther 1989; 15: 65–75

    Google Scholar 

  87. Kietzmann H, Macher E, Rihoux J-P, et al. Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy 1990; 65: 498–500

    PubMed  CAS  Google Scholar 

  88. Andri L, Senna GE, Betteli C, et al. Acomparison of the efficacy of cetirizine and terfenadine: a double blind controlled study of chronic idiopathic urticaria. Allergy 1993; 48: 358–65

    Article  PubMed  CAS  Google Scholar 

  89. Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria: a double blind randomised cross-over study. Ann Acad Med Singapore 1991; 20: 328–30

    PubMed  CAS  Google Scholar 

  90. Alomar A, De La Cuadra J, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. J Int Med Res 1990; 18: 358–65

    PubMed  CAS  Google Scholar 

  91. Burtin B, Fayol C, Marquis P, et al. Cetirizine improves quality of life as assessed by the SF-36 questionnaire (SF-36) in perennial allergic rhinitis [abstract]. J Allergy Clin Immunol 1994; 93: 163

    Google Scholar 

  92. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996; 98(2): 309–16

    Article  PubMed  CAS  Google Scholar 

  93. Watson WT, Simons KJ, Chen XY, et al. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 457–64

    Article  PubMed  CAS  Google Scholar 

  94. Masi M, Candiani R, van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immunol 1993; 4 Suppl. 4: 47–52

    Article  PubMed  CAS  Google Scholar 

  95. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its anti-allergic activity. Clin Exp Allergy 1997; 27: 1160–6

    Article  PubMed  CAS  Google Scholar 

  96. Simons FER. Prospective long term safety evaluation of the H1 -receptor antagonist cetirizine in very young children with atopic dermatitis. J Allergy Clin Immunol 1999; 104: 433–40

    Article  PubMed  CAS  Google Scholar 

  97. Ramaekers JG, Uiterwijk MM, O’Hanlon JE. Effects of loratadine and cetirizine on actual driving and psychometric test performance and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363–9

    PubMed  CAS  Google Scholar 

  98. Nicholson AN, Turner C. Central effects of the H1 antihistamine cetirizine. Aviat Space Environ Med 1998; 69: 166–71

    PubMed  CAS  Google Scholar 

  99. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during 3 day administration of cetirizine ordiphenhydramine. J Allergy Clin Immunol 1994; 94: 716–24

    Article  PubMed  CAS  Google Scholar 

  100. Seidel WF, Cohen S, Bliwise NG. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987; 59: 58–62

    PubMed  CAS  Google Scholar 

  101. Seidel WF, Cohen S, Bliwise NG. Direct measurement of daytime sleepiness after administration of cetirizine and hydroxyzine with a standardised electroencephalographic assessment. J Allergy Clin Immunol 1990; 86: 1029–33

    Article  PubMed  CAS  Google Scholar 

  102. Patat A, Stubbs D, Dunmore C, et al. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995; 48: 143–50

    Article  PubMed  CAS  Google Scholar 

  103. Volkerts ER, van Laar M. Specific review of the psychometric effects of cetirizine. Allergy 1995; 50: 55–60

    Article  PubMed  CAS  Google Scholar 

  104. Gengo F, Gabos C. Antihistamines, drowsiness and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987; 59: 53–7

    PubMed  CAS  Google Scholar 

  105. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performances measured using an automobile driving simulator. Ann Allergy 1990; 64: 520–6

    PubMed  CAS  Google Scholar 

  106. Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092–7

    Article  PubMed  CAS  Google Scholar 

  107. Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 1987; 42: 265–72

    Article  PubMed  CAS  Google Scholar 

  108. Hindmarch I, Sherwood N, Mariz S, et al. Acomparison of the effects of cetirizine and loratadine on human psychomotor activity [abstract 227]. XV International Congress of Allergology and Clinical Immunology: 1994 Jun 26–Jul 1; Stockholm

  109. Levander S, Stähle-Bäckdahl M, Hägermark Ö. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol 1991; 41: 435–9

    Article  PubMed  CAS  Google Scholar 

  110. Doms M, Vanhulle G, Baelde Y, et al. Lack of potentiation by cetirizine of alcohol-induced psychomotor disturbances. Eur J Clin Pharmacol 1988; 34: 619–23

    Article  PubMed  CAS  Google Scholar 

  111. Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995; 50: 48–54

    Article  PubMed  CAS  Google Scholar 

  112. Bickel MH. Factors affecting the storage of drugs and other xenobiotics in adipose tissue. In: B Testa, UA Meyer, editors. Advances in drug research. London: Academic Press, 1994: 25: 55–86

    Google Scholar 

  113. Simons FER, Kesselman MS, Giddins NG, et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988; II: 624

    Article  Google Scholar 

  114. Davies AJ, Harinda V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose [letter]. BMJ 1989; 298: 325

    Article  PubMed  CAS  Google Scholar 

  115. Woolsey RL, Chen Y, Freiman JP, et al. Mechanisms of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    Article  Google Scholar 

  116. Woolsey RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233–52

    Article  Google Scholar 

  117. Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlopheniramine and pyrilamine. Circ Res 1995; 76: 110–9

    Article  PubMed  CAS  Google Scholar 

  118. Rampe DE, Wible B, Brown AM, et al. Effects of terfenadine and its metabolite on a delayed rectifier K sup + channel from human heart. Mol Pharmacol 1993; 44: 1240–5

    PubMed  CAS  Google Scholar 

  119. Sale ME, Woolsey RL, Barby JT, et al. Lack of electrocardiographic effects of cetirizine in healthy humans [abstract]. J Allergy Clin Immunol 1993; 91: 258

    Google Scholar 

  120. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999; 29 Suppl. 3; 39: 163–70

    Article  Google Scholar 

  121. Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999; 353: 980

    Article  PubMed  CAS  Google Scholar 

  122. Hey J, del Prado M, Egan RW, et al. Loratadine produces antihistaminic activity without adverse CNS, ECG or cardiovascular effects in guinea pigs: comparative study with terfenadine and sedating antihistamines. Int Arch Allergy Immunol 1995; 107: 418–9

    Article  PubMed  CAS  Google Scholar 

  123. Hey J, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996; 46(2): 153–8

    PubMed  CAS  Google Scholar 

  124. Hey J, del Prado M, Kreutner W, et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model torsade de pointes. Arzneimittelforschung 1996; 46(2): 159–63

    PubMed  CAS  Google Scholar 

  125. Carmeliet E. Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 1998; 124: 663–8

    Article  PubMed  CAS  Google Scholar 

  126. Affrime MB, Lorber R, Danzig M, et al. Three months evaluation of electrocardiac effects of loratadine in humans. Allergy 1993; 47 Suppl. 16: 29

    Google Scholar 

  127. Sanders RL. Dockhorn RJ, Alderman JL, et al. Cardiac effect of acrivastine compared to terfenadine [abstract]. J Allergy Clin Immunol 1992; 89: 183

    Google Scholar 

  128. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994; 56: 295–301

    Article  PubMed  CAS  Google Scholar 

  129. Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997; 99: 860–1

    Article  PubMed  CAS  Google Scholar 

  130. Delgado LF, Pferferman A, Sole D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998; 80(4): 333–7

    Article  PubMed  CAS  Google Scholar 

  131. Lidquist M, Edwards IR. Risk of non-sedating antihistamines [letter]. Lancet 1997; 349: 1322

    Article  Google Scholar 

  132. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 835–63

    Article  Google Scholar 

  133. Warmke JW, Ganetzky B. Afamily of potassium channel genes related to eag in Drosofila and mammals. Proc Natl Acad Sci U S A 1994; 91: 3438–42

    Article  PubMed  CAS  Google Scholar 

  134. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299–307

    Article  PubMed  CAS  Google Scholar 

  135. Roy M-L, Dumanie R, Brown AM. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. Circulation 1996; 94: 817–23

    Article  PubMed  CAS  Google Scholar 

  136. Suessbrich H, Waldegger S, Lang F, et al. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385: 77–80

    Article  PubMed  CAS  Google Scholar 

  137. Bianchi L, Wible B, Arcangeli A, et al. HERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 1998; 58: 815–22

    PubMed  CAS  Google Scholar 

  138. Taglialatela M, Pannaccione A, Castaldo P, et al. The molecular basis for the lack of HERG K+ channels block-related cardiotoxicity by the H1 receptor blocker cetirizine as compared to other second-generation antihistamines. Mol Pharmacol 1998; 54: 113–21

    PubMed  CAS  Google Scholar 

  139. Deplon E, Valenzuela C, Gay P, et al. Block of human cardiac Kv1.5 channel by loratadine: voltage-, time-, and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35: 341–50

    Article  Google Scholar 

  140. Church MK, Collinson AD, Okayama Y. H1 receptor antagonists: antiallergic effects in vitro. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease: clinical allergy and immunology series. New York (NY): Marcel Dekker Inc., 1996: 117–44

    Google Scholar 

  141. Church MK. Non-H1 receptor effects of antihistamines. Clin Exp Allergy 1999; 29 Suppl. 3: 39–48

    PubMed  CAS  Google Scholar 

  142. Leprevost C, Capron M, De Vos C, et al. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine). Int Arch Allergy App Immunol 1988; 87: 9–13

    Article  CAS  Google Scholar 

  143. De Vos C, Joseph M, Leprevost C, et al. Inhibition of human eosinophil chemotaxis and of the IgE-dependent stimulation of human blood platelets by cetirizine. Int Arch Allergy Appl Immunol 1989; 88: 212–5

    Article  PubMed  Google Scholar 

  144. Sehmi R, Walsh GM, Hartneil A, et al. Modulation of human eosinophil chemotaxis and adhesion by anti-allergic drugs in vitro. Pediatr Allergy Immunol 1993; 4 (4 Suppl.): 13–8

    Article  PubMed  CAS  Google Scholar 

  145. Jinquan T, Reimert CM, Deleuran B, et al. Cetirizine inhibits the in vitro and ex vivo chemotactic responses of T lymphocytes and monocytes. J Allergy Clin Immunol 1995; 95: 979–86

    Article  PubMed  CAS  Google Scholar 

  146. Walsh GM, Moqbel R, Hartneil A, et al. Effects of cetirizine on human eosinophil and neutrophil activation in vitro. Int Arch Allergy Appl Immunol 1991; 95: 158–62

    Article  PubMed  CAS  Google Scholar 

  147. Kantar A, Oggiano N, Giorgi PL, et al. A study of the interaction between cetirizine and plasma membrane of eosinophils, neutrophils, platelets and lymphocytes using a fluorescence technique. Mediators Inflamm 1994; 3: 229–34

    Article  PubMed  CAS  Google Scholar 

  148. Okada C, Eda R, Miyagawa H, et al. Effect of cetirizine on human eosinophil Superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. Int Arch Allergy Immunol 1994; 103: 384–90

    Article  PubMed  CAS  Google Scholar 

  149. Cheria-Sammari S, Aloui R, Gormand F, et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis: effects of cetirizine. Clin Exp Allergy 1995; 25: 729–36

    Article  PubMed  CAS  Google Scholar 

  150. Koller M, Hilger RA, Rihoux J-P, et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int Arch Allergy Immunology 1996; 110: 52–6

    Article  CAS  Google Scholar 

  151. Roch-Arveiller M, Tissot M, Idohou N, et al. In vitro effect of cetirizine on PGE2 release by rat peritoneal macrophages and human monocytes. Agents Actions 1994; 43: 13–6

    Article  PubMed  CAS  Google Scholar 

  152. Mincarini M, Cagoni F, Canonica GW, et al. Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM-1/CD54 on primary cultured nasal cells. Allergy 2000; 55: 226–31

    Article  PubMed  CAS  Google Scholar 

  153. Arnold R, Rihoux J-P, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999; 29: 1681–91

    Article  PubMed  CAS  Google Scholar 

  154. Rihoux J-P, Masliah J, Bereziat G, et al. G proteins as biological targets for anti-allergic drugs? Int Arch Allergy Immunol 1997; 113(1–3): 339–41

    Article  PubMed  CAS  Google Scholar 

  155. Merlos M, Ramis I, Balsa D, et al. Inhibitory effect of rupatadine on TNF-alpha release from human monocytes and mast cell line HMC-1 [abstract 191]. J Allergy Clin Immunol 2000: 105

    Google Scholar 

  156. Eda R, Sugiyama H, Hopp RJ, et al. Effect of loratadine on human eosinophil function in vitro. Ann Allergy 1993; 71: 373–8

    PubMed  CAS  Google Scholar 

  157. Molet S, Gosset P, Lassalle P, et al. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997; 27: 1167–74

    Article  PubMed  CAS  Google Scholar 

  158. Temple DM, McCluskey M. Loratadine, an anti-histamine, blocks antigen and ionophore-induced leukotriene release from human lung in vitro. Prostaglandins 1988; 35: 549–54

    Article  PubMed  CAS  Google Scholar 

  159. Letari O, Miozzo A, Folco G, et al. Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol 1994; 266: 219–27

    Article  PubMed  CAS  Google Scholar 

  160. Holen E, Elsayed S, Nyfors A. The effect of H1 receptor antagonists on peripheral blood mononuclear cells, adenoid cells and primary cell lines. APMIS 1995; 103(2): 98–106

    Article  PubMed  CAS  Google Scholar 

  161. Masini E, Di Bello MG, Raspanti S, et al. Platelet aggregation and histamine release by immunological stimuli. Immunopharmacol 1994; 28: 19–29

    Article  CAS  Google Scholar 

  162. Kleine-Tebbe J, Josties C, Frank G, et al. Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, dese-thoxycarbonyl-loratadine. J Allergy Clin Immunol 1994; 93: 494–500

    Article  PubMed  CAS  Google Scholar 

  163. Muschen A, Mirmohammadsadegh A, Jarzebska-Deussen B, et al. Differential IL-10 receptor expression in acute versus chronic atopic eczema: modulation by immunosuppressive drugs and cytokines in normal human keratinocytes. Inflamm Res 1999; 48: 539–43

    Article  PubMed  CAS  Google Scholar 

  164. Agrawal D, Berro A, Kreutner W, et al. Anti-inflammatory properties of desloratadine (DCL): effect on eosinophil chemotaxis, adhesion and release of Superoxide anions [abstract 49]. J Allergy Clin Immunol 2000: 105

    Google Scholar 

  165. Bayram H, Devalia JL, Khair OA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol 104: 1999; 93–9

    Google Scholar 

  166. Crampette L, Mainprice B, Bloom M, et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996; 51(5): 346–9

    PubMed  CAS  Google Scholar 

  167. Eda R, Townley RG, Hopp RJ. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of Superoxide. Ann Allergy 1994; 73: 154–60

    PubMed  CAS  Google Scholar 

  168. Okayama Y, Benyon RC, Lowman MA, et al. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil and skin. Allergy 1994; 49: 246–53

    Article  PubMed  CAS  Google Scholar 

  169. Abdelaziz M, Davalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101: 410–20

    Article  PubMed  CAS  Google Scholar 

  170. Marone G, Granata F, Palumbo C, et al. Are the anti-allergic properties of H1 antihistamines of any clinical relevance? Rev Fr Allergol 2000; 40: 70–3

    Google Scholar 

  171. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81: 601–7

    Article  PubMed  CAS  Google Scholar 

  172. Amon S, Amon U, Gibbs BF. Antiallergic activity of fexofenadine in vitro [abstract 1116]. J Allergy Clin Immunol 2000: 105

  173. Kamei C, Mio M, Izushi K, et al. Antiallergic effects of major metabolites of astemizole in rats and guinea pigs. Arzneimittelforschung 1991; 41: 932–6

    PubMed  CAS  Google Scholar 

  174. Fukuishi N, Kan T, Hirose K, et al. Inhibitory effect of epinastine on Superoxide generation by rat neutrophils. Jpn J Pharmacol 1995; 68: 449–52

    Article  PubMed  CAS  Google Scholar 

  175. Taniguchi K, Urakami M, Tanaka K. Effects of various drugs on Superoxide generation, arachidonic acid release and phospolipase A2 in polymorphonuclear leukocytes. Jpn J Pharmacol 1988; 46: 275–84

    Article  PubMed  CAS  Google Scholar 

  176. Shindo K, Fukumura M, Hirai Y, et al. Effect of azelastine hydrochloride on release and production of platelet activating factor in human neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 373–7

    Article  PubMed  CAS  Google Scholar 

  177. Akamatsu H, Mitachi Y, Asada Y, et al. Effects of azelastine on neutrophil chemotaxis, phagocytosis and oxygen radical production. Jpn J Pharmacol 1991; 57: 583–9

    Article  PubMed  CAS  Google Scholar 

  178. Shindo K, Machida M, Hirai Y, et al. Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 561–6

    Article  PubMed  CAS  Google Scholar 

  179. Shindo K, Fukumura M. Azelastine hydrochloride inhibits platelet activating factor-like activity in human eosinophils. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 217–21

    Article  PubMed  CAS  Google Scholar 

  180. Kurosawa M, Hanawa K, Kobayashi S, et al. Inhibitory effect of azelastine on Superoxide generation from activated inflammatory cells measured by a simple chemiluminescence method. Arzneimittelforschung 1990; 40: 767–70

    PubMed  CAS  Google Scholar 

  181. Ezeamuzie CI, Al-Hage M. Effects of some anti-asthma drugs on human eosinophil Superoxide release and degranulation. Int Arch Allergy Immunol 1998; 115: 162–8

    Article  PubMed  CAS  Google Scholar 

  182. Hide I, Toriu N, Nuibe T, et al. Suppression of TNF-alpha secretion in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J Immunol 1997; 159: 2932–40

    PubMed  CAS  Google Scholar 

  183. Matsuo S, Takayama S. Influence of the anti-allergic agent, azelastine, on tumor necrosis factor-alpha (TNF-alpha) secretion from cultured mouse mast cells. In Vivo 1998; 12: 481–4

    PubMed  CAS  Google Scholar 

  184. Inoue H, Kubota T, Ando K, et al. Effect of azelastine on PGE2 production in fibroblasts in normal skin: the possibility of inhibition of inducible cyclooxygenase by azelastine. Life Sci 61 (12): PL171-6

  185. Hamasaki Y, Shafigeh M, Yamamoto S, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996; 76(5): 469–75

    Article  PubMed  CAS  Google Scholar 

  186. Yoneda K, Yamamoto T, Ueta E, et al. Suppression by azelastine hydrochloride of NFκB activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997; 73: 145–53

    Article  PubMed  CAS  Google Scholar 

  187. Chihara J, Yasukawa A, Yamamoto T, et al. The inhibitory effect of oxatomide on oxygen radical products from human eosinophils and an eosinophilic cell line. Arerugi 1991; 40: 689–94

    PubMed  CAS  Google Scholar 

  188. Umeki S. Effects of anti-allergic drugs on human neutrophil Superoxide generating NADPH oxidase. Biochem Pharmacol 1992; 43: 1109–17

    Article  PubMed  CAS  Google Scholar 

  189. Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999; 36: 453–96

    Article  PubMed  CAS  Google Scholar 

  190. Walsh GM. The anti-inflammatory effects of cetirizine. Clin Exp Allergy 1993; 24: 81–5

    Article  CAS  Google Scholar 

  191. Walsh GM. The effects of cetirizine on the function of inflammatory cells involved in the allergic response. Clin Exp Allergy 1997; 27: 47–53

    Article  PubMed  CAS  Google Scholar 

  192. Ventura MT, Guiliano G, Corato R, et al. Modulation of eosinophilic chemotaxis with azelastine and budesonide in allergic patients. Immunopharmacol Immunotoxicol 1998; 20: 383–98

    Article  PubMed  CAS  Google Scholar 

  193. Naclerio RM, Baroody FM. H1 receptor antagonists: antiallergic effects in humans. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease: clinical allergy and immunology series. New York (NY): Marcel Dekker Inc, 1996: 145–74

    Google Scholar 

  194. Fadel R, Heprin-Richard N, Rihoux J-P, et al. Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy 1987; 17: 373–9

    Article  PubMed  CAS  Google Scholar 

  195. Michel L, De Vos C, Rihoux J-P, et al. Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-aceter release and eosinophil recruitment in human skin. J Allergy Clin Immunol 1988; 82: 101–9

    Article  PubMed  CAS  Google Scholar 

  196. Charlesworth EN, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989; 83: 905–12

    Article  PubMed  CAS  Google Scholar 

  197. Charlesworth EN, Massey WA, Kagey-Sobotka A, et al. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992; 262: 964–70

    PubMed  CAS  Google Scholar 

  198. Fadel R, Herpin-Richard N, Dufresne F, et al. Pharmacological modulation by cetirizine and loratadine of antigen-and histamine-induced skin wheals and flares, and late accumulation of eosinophils. J Int Med Res 1990; 18: 366–71

    PubMed  CAS  Google Scholar 

  199. Fadel R, David B, Heprin-Richard N, et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet activating factor in man. J Allergy Clin Immunol 1990; 86: 314–20

    Article  PubMed  CAS  Google Scholar 

  200. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (CD54) expression on conjunctival epithelium in both early-and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95: 612–21

    Article  PubMed  CAS  Google Scholar 

  201. Varney V, Gaga M, Frew AJ, et al. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects. Clin Exp Allergy 1992; 22: 43–9

    Article  PubMed  CAS  Google Scholar 

  202. Taborda-Barata L, Jacobson M, Walker S, et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996; 26: 69–78

    Article  Google Scholar 

  203. Fasce L, Ciprandi G, Pronzato C, et al. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996; 109: 272–6

    Article  PubMed  CAS  Google Scholar 

  204. Kalayci O, Saraclar Y, Adalioglu G, et al. The effect of cetirizine on suffido leukotriene production by blood leukocytes in children with allergic rhinitis. Allergy 1995; 50: 964–9

    Article  PubMed  CAS  Google Scholar 

  205. Haye R, Annesen J, Jahnsen FL, et al. Effect of cetirizine on nasal polyps and their associated symptoms [abstract]. Allergy 1995; 50: 103

    Google Scholar 

  206. Perzanowska M, Malhotra D, Skinner SP, et al. The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res 1996; 45: 486–90

    Article  PubMed  CAS  Google Scholar 

  207. Burrows LJ, Skinner SP, Bewley AP. Bradykinin-induced wheal and flare in human skin is not mediated by histamine but is blocked by cetirizine. Allergy 1995; 50 Suppl. 26: 76

    Google Scholar 

  208. Zweiman B, Atkins PC, Moskovitz A, et al. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. J Allergy Clin Immunol 1997; 100: 341–7

    Article  PubMed  CAS  Google Scholar 

  209. Atkins PC, Zweiman B, Moskovitz A, et al. Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine. J Allergy Clin Immunol 1997; 99: 806–11

    Article  PubMed  CAS  Google Scholar 

  210. Tosca M, Ricca V, Carosso A, et al. Cetirizine treatment of allergic cough in children with pollinosis [abstract]. Allergy 1996; 51/31 Suppl.: WS112

    Google Scholar 

  211. Juhlin L, Rihoux J-P. Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. Acta Derm Venereol 1990; 70: 151–3

    PubMed  CAS  Google Scholar 

  212. Naclerio RM. Additional properties of cetirizine, a new H1 antagonist. Allergy Proc 1991; 12: 187–91

    Article  PubMed  CAS  Google Scholar 

  213. Redier H, Chanez P, De Vos C, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90: 215–24

    Article  PubMed  CAS  Google Scholar 

  214. Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993; 91: 1189–97

    Article  PubMed  CAS  Google Scholar 

  215. Caproni M, Giovannii MP, Falcos D. Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions. Int J Dermatol 1995; 34: 510–3

    Article  PubMed  CAS  Google Scholar 

  216. Fadel R, Ramboer I, Chatterjee N, et al. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects. Allergy 2000; 55: 382–5

    Article  PubMed  CAS  Google Scholar 

  217. Klementson H, Andersson M, Pipkorn U. Allergen-induced increase in non-specific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influx. J Allergy Clin Immunol 1990; 86: 466–72

    Article  Google Scholar 

  218. Campbell A, Chanal I, Czarlewski W, et al. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy 1997; 52: 1022–5

    Article  PubMed  CAS  Google Scholar 

  219. Condino-Neto A, Muscara MN, Bozza PT, et al. The effect of a 1-week administration of cetirizine on the chemotaxis and Superoxide anion production of neutrophils from healthy volunteers. Int J Clin Pharmacol Ther 1996; 34: 96–100

    PubMed  CAS  Google Scholar 

  220. Turner CR, Andersen CJ, Smith WB, et al. Characterisation of a primate model of asthma using anti-allergy/anti-asthma agents. Inflamm Res 1996; 45: 239–45

    Article  PubMed  CAS  Google Scholar 

  221. Pasquale CP, e Silva PM, Lima MCR, et al. Suppression by cetirizine of pleurisy triggered by antigen in actively sensitised rats. Eur J Pharmacol 1992; 223: 9–14

    Article  PubMed  CAS  Google Scholar 

  222. Bandeira-Melo C, e Silva PM, Cordeiro RS, et al. Pleural fluid eosinophils suppress local IgE-mediated protein exudation in rats. J Leukoc Biol 1995; 58: 395–402

    PubMed  CAS  Google Scholar 

  223. Johnson HG, McNee ML, Nugent RA. Canine in vivo tracheal chemotaxis of eosinophils to antigen in sensitised dogs: inhibition by a steroid, a systemic lavaroid U-78517F, and several topical antihistamines. Am Rev Respir Dis 1992; 146: 621–5

    PubMed  CAS  Google Scholar 

  224. Naclerio RM. Effects of antihistamines on inflammatory mediators. Ann Allergy 1993; 71(3): 292–5

    PubMed  CAS  Google Scholar 

  225. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 507–11

    Article  PubMed  CAS  Google Scholar 

  226. Rihoux J-P, Fadel R. Bradykinin-induced immediate skin reactions and H1-blockade. Int Arch Allergy Immunol 1995; 107; 421–2

    Article  PubMed  CAS  Google Scholar 

  227. Jacobi HH, Skov PS, Poulsen LK, et al. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999; 103: 768–72

    Article  PubMed  CAS  Google Scholar 

  228. Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997; 27: 1175–83

    Article  PubMed  CAS  Google Scholar 

  229. Ciprandi G, Buscaglia S, Marchesi E, et al. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1994; 100: 185–9

    Article  Google Scholar 

  230. Ciprandi G, Pronzato C, Ricca V, et al. Loratadine reduces ICAM-1 expression on conjunctiva after specific challenge in pollen allergic patients. Allergy 1998; 53: 545–6

    Article  PubMed  CAS  Google Scholar 

  231. Malhotra D, Keefe M, Rihoux J-P, et al. Cetirizine and loratadine do not inhibit codeine-induced histamine release in human skin in vivo [abstract]. Allergy 1995; 50: 75

    Article  Google Scholar 

  232. Juhlin L, Pihl-Lundin I. Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. Acta Derm Venereol 1992; 72: 197–200

    PubMed  CAS  Google Scholar 

  233. Purello-D’Ambrosio F, Isola S, Ricciardi L, et al. A controlled study of the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES). Clin Exp Allergy 1999; 29: 1143–7

    Article  PubMed  Google Scholar 

  234. Raptopoulou-Gigi M, Ilonidis G, Orphanou-Koumerkeridou H, et al. The effect of loratadine on activated cells of the nasal mucosa in patients with allergic rhinitis. J Invest Allergol Clin Immunol 1993; 3: 192–7

    CAS  Google Scholar 

  235. Grief L, Persson CG, Svensson C, et al. Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic patients. J Allergy Clin Immunol 1995; 96: 97–103

    Article  Google Scholar 

  236. Bousquet J, Lebel B, Chanal I, et al. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1998; 82: 881–7

    Article  Google Scholar 

  237. Roquet A, Raud J, Hallden G, et al. Effects of loratadine on anti-IgE-induced inflammation, histamine release and leukocyte recruitment in skin of atopics. Allergy 1995; 50: 414–20

    Article  PubMed  CAS  Google Scholar 

  238. Andersson M, Nolte H, Baumgarten C, et al. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991; 47: 540–6

    Article  Google Scholar 

  239. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effect of terfenadine at different dosages on conjunctival provocation test. Allergy 1992; 47: 309–12

    Article  PubMed  CAS  Google Scholar 

  240. Ciprandi G, Pronzato C, Ricca V, et al. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy 1995; 25: 871–8

    Article  PubMed  CAS  Google Scholar 

  241. Chand N, Harrison JE, Rooney SM, et al. Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs. Allergy 1993; 48: 624–6

    Article  PubMed  CAS  Google Scholar 

  242. Massey WA, Charlesworth EN, Freidhoff L, et al. Cutaneous IgE-mediated inflammatory lesion size is inhibited by an H1 antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro. Clin Exp Allergy 1993; 23: 399–405

    Article  PubMed  CAS  Google Scholar 

  243. Naclerio RM, Kager-Sobotka A, Lichenstein LM, et al. Terfenadine, an anti H1 antihistamine inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990; 142: 167–71

    PubMed  CAS  Google Scholar 

  244. Joetham A, Takeda K, Ishizuka T, et al. The effects of terfenadine acid metabolite (TAM) on airway inflammation and airway hyperresponsiveness in ovalbumin-sensitised mice [abstract 736]. Am J Respir Crit Care Med 1997: 155

  245. Hoechst Marrion Roussel. Fexofenadine prescribing information. Kansas City (MO): Hoechst Marrion Roussel, 1996

    Google Scholar 

  246. Simons FER, Johnston L, Gu X, et al. Suppression of the early and late cutaneous allergic responses using the H1-Receptor antagonist fexofenadine and the cysteinyl leukotrienel-antagonist montelukast [abstract 793]. J Allergy Clin Immunol 2000: 105

  247. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokines in nasal secretions after nasal antigen challenge [abstract 602]. J Allergy Clin Immunol 2000: 105

  248. Reunala T, Brummer-Korvenkontio H, Petman L, et al. Effect of ebastine on mosquito bites. Acta Derm Venereol 1997; 77: 315–6

    PubMed  CAS  Google Scholar 

  249. Campbell A, Michel F-B, Brenard-Oury C, et al. Ebastine has more than an antihistamine effect. Drugs 1996; 52 Suppl. 1: 15–9

    Article  PubMed  CAS  Google Scholar 

  250. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittelforschung 1998; 48: 173–8

    PubMed  CAS  Google Scholar 

  251. Goldhill J, Pichat P, Roome N, et al. Effect of mizolastine on visceral afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung 1998; 48: 179–84

    PubMed  CAS  Google Scholar 

  252. Oddera S, Cagnoni F, Dellacasa P, et al. Effects of mizolastine in vitro on hyman immunocompetent and airway cells; evidence for safety and additional property. Int Arch Allergy Immunol 2000; 123: 162–9

    Article  PubMed  CAS  Google Scholar 

  253. Michel L, Murrieta-Aguttes M, Jean-Louis F, et al. Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: effect of mizolastine. Ann Allergy Asthman Immunol 2000; 85: 64–9

    Article  CAS  Google Scholar 

  254. Wedi B, Novacovic V, Koerner W, et al. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression: inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol 2000; 105: 552–60

    Article  PubMed  CAS  Google Scholar 

  255. Hoshino M, Nakamura Y. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997; 114: 285–92

    Article  PubMed  CAS  Google Scholar 

  256. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997; 27: 182–91

    Article  PubMed  CAS  Google Scholar 

  257. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98: 1088–96

    Article  PubMed  CAS  Google Scholar 

  258. Shinoda M, Watanabe N, Suko T, et al. Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am JRhinol 1997; 11: 237–41

    Article  CAS  Google Scholar 

  259. Chand N, Nolan K, Diamantis W, et al. Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea-pigs. Allergy 1986; 41: 473–8

    Article  PubMed  CAS  Google Scholar 

  260. Ciprandi G, Catrullo A, Tosca M, et al. Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. J Invest Allergol Clin Immunol 1999; 9: 35–8

    CAS  Google Scholar 

  261. Tamaoki J, Yamawaki I, Tagaya E, et al. Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways. Am J Physiol 1999; 276 (2 Pt 1): L351–7

    PubMed  CAS  Google Scholar 

  262. Ito H, Nakamura Y, Takagi S, et al. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung 1998; 48: 1143–7

    PubMed  CAS  Google Scholar 

  263. De Weck AL, Derer T, Bahre M. Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. Clin Exp Allergy 2000; 30: 283–7

    Article  PubMed  Google Scholar 

  264. Ciprandi G, Buscaglia S, Pronzato C, et al. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ann Allergy 1995; 75: 446–52

    CAS  Google Scholar 

  265. Ciprandi C, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993; 91: 783–92

    Article  PubMed  CAS  Google Scholar 

  266. Scadding GK. Clinical assessment of antihistamines in rhinitis. Clin Exp Allergy 1999; 29 Suppl. 3: 77–81

    PubMed  CAS  Google Scholar 

  267. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 135–40

    Article  Google Scholar 

  268. Weiner JM, Ambrason MJ, Puy RM. Intranasal corticosteroids versus H1 receptor antagonists in allergic rhinitis: systematic review of randomised control trials. BMJ 1998; 317: 1624–9

    Article  PubMed  CAS  Google Scholar 

  269. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86: 540–7

    Article  PubMed  CAS  Google Scholar 

  270. Frossard N, Melac M, Benabdessalam O, et al. Consistency of the reactivity of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 1998; 80: 61–5

    Article  PubMed  CAS  Google Scholar 

  271. Coulie PJ, de Vos C, Ghys L, et al. Pharmacologic modulation by cetirizine 2HCl and loratadine of the histamine-induced skin reaction in mice and in humans. Drug Dev Res 1989; 17: 199–206

    Article  CAS  Google Scholar 

  272. Van Neste D, De Brouwer B, Tasst C. Laser Dopplerflowmetry on histamine-induced skin response. Eur J Dermatol 1995; 5: 537–41

    Google Scholar 

  273. De la Cuadra J, Teruel M, Teixido P. Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double blind study. Dermatology 1994; 188: 131–4

    Article  PubMed  Google Scholar 

  274. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533–40

    Article  PubMed  CAS  Google Scholar 

  275. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33

    Article  PubMed  CAS  Google Scholar 

  276. Finn AF, Kaplan AF, Fretwell R, et al. A double-blind placebo controlled trial of fexofenadine HCl in the treatment of chronic idiopathic uricaria. J Allergy Clin Immunol 1999; 104: 1071–8

    Article  PubMed  CAS  Google Scholar 

  277. Simons FE, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997; 79(6): 530–2

    Article  PubMed  CAS  Google Scholar 

  278. Grant JA, Danielson L, Rihoux J-P, et al. A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine and loratadine versus placebo in suppressing the cutaneous response to histamine. Allergy 1999; 54: 700–7

    Article  PubMed  CAS  Google Scholar 

  279. Holgate ST, Finnerty JP. Antihistamines in asthma. J Allergy Clin Immunol 1989; 83: 537–47

    Article  PubMed  CAS  Google Scholar 

  280. Meltzer EO. To use or not to use antihistamines in patients with asthma [editorial]. Ann Allergy 1990; 64: 183–6

    PubMed  CAS  Google Scholar 

  281. Akagi K, Townley RG. Spontaneous histamine-release and histamine content in nonnal subjects and subjects with asthma. J Allergy Clin Immunol 1989; 83: 742–9

    Article  PubMed  CAS  Google Scholar 

  282. Casale TB, Wood D, Richerson HB. Direct evidence of a role for mast cells in pathogenesis of antigen-induced broncho-constriction. J Clin Invest 1987; 80: 1507–11

    Article  PubMed  CAS  Google Scholar 

  283. Casale TB, Wood D, Richerson HB. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987; 79: 1197–203

    Article  PubMed  CAS  Google Scholar 

  284. Malick A, Grant J. Antihistamines in the treatment of asthma. Allergy 1997; 52 Suppl. 34: 55–66

    Article  PubMed  CAS  Google Scholar 

  285. Wood-Baker R, Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91: 1005–14

    Article  PubMed  CAS  Google Scholar 

  286. Wood-Baker R, Holgate ST. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine-and methacholine-induced bronchoconstriction in patients with asthma. Agents Actions 1990; 30(1-2): 284–6

    Article  PubMed  CAS  Google Scholar 

  287. Chyrek-Borowska S, Siergiejko Z, Michalska I. The effects of a new generation of H1 antihistamines (cetirizine and loratadine) on histamine release and the bronchial response to histamine in atopic patients. J Invest Allergol Clin Immunol 1995; 5(2): 103–7

    CAS  Google Scholar 

  288. Ghosh SK, Rafferty P, De Vos C, et al. Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin Exp Allergy 1993; 23: 524–7

    Article  PubMed  CAS  Google Scholar 

  289. Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on the early and late asthmatic responses to allergen and the associated increases in airways responsiveness. Clin Exp Allergy 1996; 26: 909–17

    Article  PubMed  CAS  Google Scholar 

  290. Bruttmann G, Pedrali P, Arendt C, et al. Protective effect of cetirizine in patients suffering from pollen asthma. Ann Allergy 1990; 64: 224–8

    PubMed  CAS  Google Scholar 

  291. Bousquet J, Emonot A, Germouty J, et al. Double-blind multicenter study of cetirizine in grass pollen-induced asthma. Ann Allergy 1990; 65: 504–58

    PubMed  CAS  Google Scholar 

  292. Dijkman JH, Hekking PR, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy 1990; 20: 483–90

    Article  PubMed  CAS  Google Scholar 

  293. Rafferty P, Ghosh SK, de Vos C, et al. Effect of oral and inhaled cetirizine in allergen-induced bronchoconstriction. Clin Exp Allergy 1993; 23: 528–31

    Article  PubMed  CAS  Google Scholar 

  294. Kopferschmitt-Kubler MC, Couchot A, Pauli G. Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response. Ann Allergy 1990; 65: 501–53

    PubMed  CAS  Google Scholar 

  295. Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 1996; 153: 122–7

    PubMed  CAS  Google Scholar 

  296. Chervinsky P, Grossman J, Freitag JJ. Duration of action of a single dose of azelastine in patients with chronic asthma. J Asthma 1995; 32: 141–5

    Article  PubMed  CAS  Google Scholar 

  297. Anonymous. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma: azelastine-asthma study group. J Allergy Clin Immunol 1996; 97: 1218–24

  298. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomised, placebo controlled trial. J Allergy Clin Immunol 1995; 95: 923–32

    Article  PubMed  CAS  Google Scholar 

  299. Aaronson DW Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440–6

    Article  Google Scholar 

  300. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol and both together versus placebo in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 96: 174–81

    Article  PubMed  CAS  Google Scholar 

  301. Kjellman N-IM. Is there a place for antihistamines in the treatment of perennial asthma? Pediatr Allergy Immunol 1993; 4 Suppl. 4: 38–43

    Article  PubMed  CAS  Google Scholar 

  302. Rafferty P, Jackson L, Smith R, et al. Terfenadine, a potent antihistamine Hi-receptor antagonist in the treatment of grass pollen-sensitive asthma. Br J Pharmacol 1990; 30: 229–35

    Article  CAS  Google Scholar 

  303. Taytard A, Beaumont D, Pujet JC, et al. Treatment of bronchial asthma with terfenadine; a randomised controlled trial. Br J Pharmacol 1987; 24: 743–6

    Article  CAS  Google Scholar 

  304. Kroll VM, Nothofer B, Werdermann K. Allergic bronchial asthma treated with loratadine. Fortschr Med 1993; 111: 76–8

    PubMed  CAS  Google Scholar 

  305. Dirksen A, Engel T, Frolund L, et al. Effect of a non-sedative antihistamine (loratadine) in moderate asthma: a double-blind, controlled clinical crossover trial. Allergy 1989; 44: 566–71

    Article  PubMed  CAS  Google Scholar 

  306. Ekstrom T, Osterman K, Zetterstrom O. Lack of effect of loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol 1995; 75(3): 287–98

    PubMed  CAS  Google Scholar 

  307. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781–8

    Article  PubMed  CAS  Google Scholar 

  308. Mygind N, Dahl R, editors. The nose and the paranasal sinuses in asthma. Allergy 1999; 54 Suppl. 57: 7–159

    Article  Google Scholar 

  309. Early Treatment of the Atopic Child (ETAC) Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine on this progression in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9: 116–24

    Article  Google Scholar 

  310. Shamshi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharm 2000; 15: S3–30

    Article  Google Scholar 

Download references

Acknowledgements

The authors extend their thanks to Dr J. P. Rihoux and Dr C. de Vos of UCB Pharma, S.A. and to Mrs C. Convery Walsh of the University of Aberdeen for their valuable comments on the manuscript and again to Mrs Convery Walsh for comprehensive editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Garry M. Walsh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walsh, G.M., Annunziato, L., Frossard, N. et al. New Insights into the Second Generation Antihistamines. Drugs 61, 207–236 (2001). https://doi.org/10.2165/00003495-200161020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161020-00006

Keywords

Navigation